SMMT
Summit Therapeutics PLCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$14.58B
P/E Ratio
—
EPS
$-1.44
Beta
-1.37
52W High
$36.91
52W Low
$13.83
50-Day MA
$15.92
200-Day MA
$19.83
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
3.72
PEG Ratio
0.00
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 705,000 |
| EBITDA | $-1.09B |
| Operating Margin | 0.00% |
| Return on Equity | -206.10% |
| Return on Assets | -115.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.85 |
| Price-to-Book | 22.81 |
| Price-to-Sales (TTM) | 3891.31 |
| EV/Revenue | 6425.28 |
| EV/EBITDA | -5.32 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $775.37M |
| Float | $133.88M |
| % Insiders | 82.62% |
| % Institutions | 15.50% |
Analyst Ratings
Consensus ($29.52 target)
1
Strong Buy10
Buy4
Hold1
Strong SellData last updated: 4/9/2026